[...Dr.?] Reddy's, as well as MVN, our Chief Financial Officer.

Our quarterly financial results have been published earlier today and are available on our website for your reference. We will start today's call with MVN providing an overview of our financial performance for the quarter.

Following that, Erez will share his insights on key business highlights as well as the company's strategic outlook. We will then open the floor for questions.

All commentary and analysis during this call are based on our IFRS consolidated financial statements. Please note that certain non-GAAP financial measures may also be discussed.

Reconciliations to the corresponding GAAP measures are included in our press release. I would like to remind everyone that the safe harbor provisions outlined in our press release today apply to all forward-looking statements made during this call.

Before we proceed, I would like to call out a few housekeeping points. All participants will be in the listen-only mode during the opening remarks.

Should you need any technical assistance during the call, please use the chat function on your Zoom application. The chat will not be monitored for any questions to the management.

The session is being recorded, and both the recording as well as the transcript will be made available on our website shortly. Please note that this call is the proprietary material of Dr.

Reddy's Laboratories Limited and may not be rebroadcast or quoted in any media or public forum without prior written consent from the company. With that, let me hand the call over to MVN to present the financial highlights for the quarter.

Over to you, MVN.

Thank you, Aishwarya. Greetings to everyone on the call.

It is my pleasure to walk you through our financial performance for the first quarter of FY '27. The business reported revenue decline of 5.6% and an EBITDA margin of 12.5% for the quarter, reflecting the impact of lower lenalidomide revenues, which contributed to the corresponding period last year, as well as a provision of ₹240 crores for inventory and other costs associated with the recent semaglutide API-related challenges.

Notably, the underlying base business, excluding lenalidomide, continued to deliver healthy double-digit growth across all key geographies, including North America, supported by new product launches and favorable currency movements. All financial figures in this section are translated into US dollars using a convenience translation rate of ₹94.66, the exchange rate prevailing as of June 30th, 2026.

Consolidated revenue stood at ₹8,071 crores, which is $853 million, a decline of 5.6% year-over-year and a growth of 7.4% on a sequential basis. Strong performance across key markets, further aided by favorable forex, was offset by lower lenalidomide sales.

NRT revenues declined primarily due to change in operating model post-integration, under which rebates and discounts are offered to distributors and recognized net of revenues, as compared to the transition period when sales were managed by the seller, Haleon. This change in operating model is profit neutral.

Consolidated gross profit margin was at 46.5%, a decrease of 1,039 basis points year-over-year and an increase of 169 basis points sequentially. The decline in margins during the quarter was largely on account of lower lenalidomide sales, the semaglutide API-related provision mentioned earlier, as well as higher solvent costs on account of Middle East conflict.

The reported gross margin was 51.6% for Global Generics and 4.5% for PSAI. Excluding the semaglutide API-related provision mentioned earlier, the overall margin was 49.4%, while that for Global Generics was 53.8% and for PSAI was at 12.9%.

The SG&A spend was at ₹2,882 crores, an increase of 12% and 4% sequentially, accounting for 36% of revenues. The year-over-year increase was primarily driven by higher personnel costs due to annual increments, adverse forex movement, targeted investments in the branded business, as well as elevated freight costs arising from disruptions related to the Middle East crisis.

The R&D spend was at ₹577 crores, declined by 8% year-over-year and up 6% sequentially, accounting for 7.1% of revenues and reflecting lower biosimilar development expenditure as compared to the previous year. The underlying EBITDA, including other income, stood at ₹1,009 crores for the quarter, which is $107 million, a decrease of 1,416 basis points year-over-year and 55 basis points sequentially, reflecting a margin of 12.5% of the revenues.

Excluding the semaglutide API-related provision, the margin was at 15.4%. As a result, the profit before tax was ₹553 crores, that is $58 million, representing a margin of 6.8%.

Excluding the semaglutide API-related provision, the margin was at 9.8%. Effective tax rate for the quarter was 21.3%, compared to 26% in the corresponding period last year.

The ETR for the quarter was lower primarily due to reversal of previously recognized tax provisions no longer required consequent to the favorable resolution of the tax assessment pertaining to earlier year and favorable jurisdictional mix for the quarter, in comparison to the same period in the previous year. Profit after tax attributable to equity holders of the parent for the quarter stood at ₹443 crores, which is $47 million, a margin of 5.5% on the revenues before adjusting for the semaglutide API-related provision mentioned earlier.

Diluted EPS for the quarter is ₹5.32. Operating working capital as of 30th June, 2026 was ₹14,353 crores, which is $1.52 billion, a decrease of ₹81 crores over 31st March, 2026.

CapEx cash outflow for the quarter stood at ₹307 crores, which is $32 million. Cash flow during the quarter before acquisition-related payout was negative ₹216 crores, which is negative of $23 million.

As of June 30th, 2026, we have a net cash surplus of ₹3,057 crores, which is $323 million. Foreign currency cash flow hedges executed through derivative instruments during the period are as follows: $354 million hedged using combination of forwards, risk reversal options, scheduled to mature by March 2027.

These contracts are hedged at the rate of 92.34 to 94.63 per US dollar. RUB 2.8 billion hedged at a fixed rate of 1.26 per Russian ruble with maturity falling within the next 3 months.

With this, I now request Erez to take us through the key business highlights.

Thank you, MVN, and good day for all of you. We appreciate you joining us today, and thank you for your continued interest in our company.

We remain consistent in our strategic priorities and committed to delivering growth and profitability through disciplined execution as the operating environment continues to evolve. We are focused on strengthening our base business and building future growth engines in peptides, biosimilar, consumer health, and innovation, while pursuing targeted business development initiative to augment our organic growth effort.

The underlying base business delivered healthy double-digit growth across all key geographies, including North America. The quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives, and other associated costs, as well as the conflict in the Middle East.

Excluding this impact, we estimate that the EBITDA margin would have been in the high teens. We are working towards resolving the issue and are planning to resume semaglutide commercial supplies by November.

Importantly, there is no risk to any patient who has consumed the product. Patient safety and product quality remain our highest priorities and will continue to guide us in every decision we make.

We remain confident of a strong second half of the fiscal, with the resumption of semaglutide supplies. The strength of our base business and our ongoing productivity initiatives will continue to support double-digit base business growth and steady margin improvement.

Let me now walk you through some of the key highlights of the quarter. We commercialized a few key complex generic products, including the anti-cancer drug bosutinib, a first-to-market launch with the 180 days of generic drug exclusivity for the 400 mg strength, and nintedanib used in the treatment of lung disease in the United States.

In Canada, we are first company to secure approval for the launch semaglutide for the treatment of type 2 diabetics. We launched oral semaglutide in India and remain committed to building this important metabolic franchise, complemented by nutrition offerings such as Celevida GLP+ through our collaboration with Nestlé.

We continue to make progress bringing innovation to patient in underserved markets through partnership. Our in-licensed novel therapy, toripalimab, for treatment of nasopharyngeal carcinoma, has entered the 100-CR club in less than 2 years of launch in India.

During the quarter, we partnered with Innoviva Specialty Therapeutics to develop and commercialize XACDURO, used in treatment of hospital-acquired bacterial pneumonia, in selected markets across South and Central America, the Caribbean, Russia, and CIS countries. Through our collaboration with GARDP and our subsidiary, Aurigene Pharmaceutical Services, we achieved an important milestone in our access agenda by securing Thai FDA approval for zoliflodacin, a first-in-class treatment for uncomplicated gonorrhea.

The approval came just 6 months after the US FDA approval, making Thailand the first LMIC country to approve the product. On the regulatory front, the US FDA completed a pre-license inspection (PLI) at our biologics manufacturing facility in Bachupally, Hyderabad in June 2026 and issued a Form 483 with seven observations, which we already responded well within the stipulated timelines.

Our commitment to good governance and sustainability continues to be recognized globally. During the quarter, we celebrate 25 years of our New York Stock Exchange listing, reinforcing our distinction as the first and only Indian pharmaceutical company listed at the exchange, as well as our commitment to global best practices in governance, compliance, and capital market access.

FTSE Russell placed us as the top 1% worldwide, while TIME-Statista ranked us 165th globally and 5th among Indian companies among the world's most sustainable companies. Let me take you through the key business highlights for the quarter.

Please note that all the financial figures mentioned are reported in their respective local currencies. Our North America generic business reported revenue of $236 million for the quarter, accounting for 27% of our overall revenue and reflecting a decline of 41% year-over-year and a growth of 19% sequentially.

The year-on-year decline was primarily on account of lower revenue lenalidomide. The underlying base business delivered double-digit growth, aided by new product launches during the quarter.

During the quarter, we launched six new products in the region, including complex generic such as bosutinib and nintedanib, and we remain on track to bring more such products to the market as we progress through the year. Our branded franchise, including India, emerging markets, and consumer health business in nicotine replacement therapy, or NRT, together accounted for 42% of our overall revenues and remain an important source of stable margins for the company.

Our emerging markets business recorded revenue of ₹1,833 crores, accounting for 23% of our overall revenues and reflecting a robust growth of 31% year-on-year and 2% quarter-on-quarter. Growth was driven by new product launches across markets and favorable currency movement.

During the quarter, we introduced 43 new products across countries. Our India base revenues were ₹1,780 crores, accounting for 21% of our overall revenues and delivering a robust double-digit year-on-year growth of 17% and 10% sequentially.

This performance was primarily driven by the innovation franchise, new launches, including acquired brands, price increase, and volume growth. IQVIA June 2026 data highlights our continued outperformance of the Indian pharmaceutical market, a moving quarterly total growth of 14.6% versus 13.5% for the IPM; in the moving annual total (MAT), growth of 13.5% versus 11.1% for the market.

Our IPM rank stood at nine for the quarter and 10 for the year. We launched seven new brands during the quarter, further enhancing our domestic presence.

Our European business, which include NRT, posted revenue of $131 million for the quarter, accounting for 18% of our overall revenues. Revenues were broadly in line with the corresponding period last year and declined 3% sequentially, on account of a price erosion as well as the impact of operating model changes post NRT integration explained by MVN, offsetting the contribution from new product launches in the generics.

During the quarter, we launched 24 new generic products across markets, further expanding our European product portfolio. Our PSAI business reported revenues of $91 million, accounting for 11% of the overall revenues.

Revenues declined 5% year-over-year and 10% sequentially, primarily on account of lower API volume uptake. During the quarter, we filed 38 drug master files globally.

We remain focused on strengthening our core business while building the next wave of growth across peptides, biosimilar, consumer health, and innovation. We continue to advance key products such as semaglutide and abatacept, improve operational efficiency, and pursue value-accretive business development opportunities to drive long-term value creation.

With that, I invite your questions as we move into the Q&A session.

Thank you very much, Erez. We will now begin the question and answer session.

To join the question queue, please use the raise hand option available on the bar at the bottom of your Zoom application. If you wish to exit the question queue, you may click on the lower hand option.

Participants are requested to not ask more than two questions at a time and rejoin the queue in case of any incremental queries. I would like to reiterate that the chat will not be monitored for any questions to the management.

However, in case of any technical concerns, please do feel free to use that option. The first question is from the line of Neha Manpuria from Bank of America.

Neha, please go ahead.

Yeah. My first question is on the EBITDA margin guidance that we had mentioned, that we should be able to get to 20% EBITDA, even without sema.

Now, given how the quarter shaped up, even if I were to adjust for sema, Middle East, I think you mentioned high teens. How should we think about the margin improvement from here, even assuming that there's still uncertainty about when and how much sema comes back?

Neha, just a technicalities, the first part of the question, if you can repeat, we heard you from the middle. Okay.

My question was that we'd given a guidance of 20% margins excluding sema. Just wanted to get a sense of how we improve the current high teens margin that you've indicated adjusted for sema and the Middle East impact, given that we're still uncertain about when sema comes back and how much it comes back in the second half.

Neha, just to make sure that that if we are taking out from the 12.5%, and we take out the impact of what we provide plus, and hear that, what we did not sell, just to make sure that and and in addition to PLI and the rest of the stuff, what I say the high teens, it's actually around 18%, okay? This quarter, the equivalent of the 19% last quarter, it's 18% for this quarter.

We are still, I maintain the what we discussed a few weeks ago, that we are in the neighborhood of the 20% and likely to stay, and that's what we are saying we will do in the next quarter, including the quarter next quarter, which will will not be with semaglutide. That's still the case to be in the neighborhood of the 20%.

As we will resume, because we with the assumption that we will come back with semaglutide in November, of course, under this assumption, the margins will be higher than that. We are maintaining what we have discussed in June.

Understood. A second question is on the US business.

There seems to be a decline quarter-on-quarter despite the fact that we launched Canada, we had bosutinib. I'm adjusting the shelf stock adjustment in the base quarter here.

What exactly happened in the US, because given we had the bosutinib FTF launch, I would have assumed some channel filling as well as the Canada supplies.

Nothing happened. It's actually in the right direction.

There were some timing of procurement of the product. The launch of the product was very successful.

Overall, I'm still maintaining a double-digit growth for the US market. Q-on-Q, as you saw, already in this quarter we grew double digit, and it will continue throughout the year.

It's a double-digit growth in the United States. It's just timing of product and nothing special.

Okay. Thank you so much.

Thanks, Neha. The next question is from the line of Dr.

Kunal Dhamesha from Macquarie. Kunal, go ahead, please.

Hi, good evening. Thank you for the opportunity.

A first question on abatacept update. Two aspects here.

One on plant inspection where we have got seven observations and we have submitted the response. Let's say when we compare the observation with the last inspection, which had five observations, how does those compare?

Second aspect, from an ongoing dialogue perspective with the US FDA on the product approval, what are the types of query we are receiving? Is it on data on the clinical side, manufacturing related, CMC related?

Color here would be helpful.

Sure. The observation, the seven, were very different than those got, and we believe that are addressable.

We sent all the relevant information to the US FDA on Friday, which was well within the stipulated time. This is undergone.

Now we will seek a feedback, obviously, from the FDA of what we submitted. As related to the BLA, we did not receive any query as we speak.

The goal date of the product is still in December, and this is still intact. We did not have any query or any ask as of date.

Sure. On that, let's say, inspection, what is your understanding?

Would it require another inspection or the response you have submitted would suffice?

To my opinion, we should get approval. Sure.

Sure. That's the first question.

Second question is some of the productivity measures that we have talked about in the past, right, that we will try to improve the efficiencies. The way I see it, when I look at the SG&A expense without R&D, after removing R&D, Q-on-Q is still higher, right?

Is there any specific cost saving measures are we undertaking? If yes, what's the quantum in terms of saving that we can see and when those measures would be visible in the overall performance?

Kunal, MVN this side. Even we said our absolute SG&A amount FY '26 FY '26 largely in line with FY '26 actuals.

This quarter, because whatever growth you have seen, largely that growth is on account of adverse forex rates movement, as well as there is a elevated freight cost on account of the Middle East conflict. These two is almost what the growth you have seen on either Q-on-Q or on the year-over-year, almost as a 75% to 80% on account of these two factors.

Otherwise, absolute amount is almost if you take it out, and then is not a much significant increase.

Just to add to what MVN said, we are planning to grow a double digit, and we are planning to grow the associate cost by a low single digit. The productivity measures will be primarily that the sales that associate, obviously, with this call, S&M, will grow much faster than the expenses.

As we grow in most of our 52% now of our business is branded markets, naturally, in such a case, we need S&M to grow the business. What is important, they will grow the sales much faster than the cost.

In this case, we are talking about the gap of 10% to 12% between the sales growth and the cost growth, and that's where the productivity you are going to see.

When should we start this difference in the growth? I assume it would be gradual, right, eventually, or it's just linked to the revenue and not any specific cost measure?

No, it is. You already see that.

I know it's hard because of all those one-time activities and or war activities, but you already see it, and as time will go by, it's obviously will see it more. Most of the S&M is in emerging market.

The growth in emerging market is right now north of 15% and in some places more than 20%, while the cost in a very low single digit growth if we take out the one-time activities.

Sure. Last one, if I may just squeeze in, one is we have around ₹3,000 crore of cash on the balance sheet, right?

What kind of opportunities are we looking at from the business development activity? Secondly, on today's announcement from US president on tariffs on generics as to how we think about the overall development.

I know the details are missing, but what would be your initial impression of that and how would you tackle that? Thank you.

Sure. The tariff was the second.

₹3,000

crores

cash.

The cash. Okay.

We are engaged in business development. I also mentioned it in my script.

There are actually quite a few deals that we are engaging in all sectors, in generics, in innovation, in biosimilars. Hopefully, we can announce those deals as we sign it.

The cash in the balance sheet will be used for inorganic. On the tariff, we've been there last year.

It's a tweet, and between tweet to the reality, a lot of things likely to happen. As we speak, I don't see any reason to be concerned, even according to the tweet, we are supposed to have 2 years of without tariff.

It's not practical to move any facility in 2 years. It well, everybody know it well.

I'm assuming that it's an opening for a discussion and dialogue. Both the IPA here in India as well as association in the United States already engage on that.

We will see how it'll evolve. Personally, I don't at this stage give too much weight to that.

Also,

if I may add, almost 25% to 30% of our revenues are actually being manufactured by CMOs in the US, we already have that as a starting point.

I would not give too much weight at this stage for that. Let's see how it evolve.

We've been there last year, and between what we started and how it end, it was very, very different.

Sure. Thank you, and all the best.

Thank you.

Thanks, Kunal. The next question is from the line of Tausif Shaikh from BNP Paribas Exane.

Tausif, please go ahead.

Thanks, Aishwarya, for the opportunity. Good evening.

First view question on semaglutide pens and API. Can you tell us how many pens has Dr.

Reddy able to sell during the quarter and a broad-based breakup regional-wise would be helpful?

180,000. We sold 180,000 pens before we stopped.

We were supposed to sell more, by the way, but obviously, that's also part of the reason why there is relatively high level of provision that we have to do on material and batches that we're not use. Obviously, most of it will be for the market of Canada.

We have also for India as well. We are still maintaining what I said 9 days ago that with assumption that we will finish, and this is still the timelines, that in around the third week of September, we are supposed to finish all the testing of the API and then supply to our partners, one source.

We have the slotting and agreement with them. If everything will go well, we should be able to give to the market 6 to 7 million pens between November and March.

That's still the same place that we are.

That's helpful. Second question on the sema API.

Just wanted to confirm that Dr. Reddy is also supplying this API to many global pharma manufacturer player who are also your competitors in Canada and other markets.

Just want to understand your strategy over here, means how much percent of capacity Dr. Reddy plans to keep for captive consumption for the future?

No, we have plenty of capacity. The theoretical capacity, I'm saying theoretical because we need to scale up in the satisfactory manner, but we have plenty of capacity for both third party as well as ourselves.

We are talking about the theoretical can come to 550, but let's say even with the non-scale-up, it can be more north of 300 as capacity. At this stage, not relevant.

It's more about the quality of the API, not the capacity.

That's helpful. A last question, abatacept.

What would be your timeline for the launch if the product has to be approved from the CMO side? Can we expect some delay from the earlier guidance which we have planned in calendar year 2027?

Abatacept is not out of a CMO. Abatacept is made by our own facility in Bachupally.

That's the facility that underwent the FDA inspections. The timing is launch upon approval.

The goal date is December, obviously, we hope for that. We need to see whether we will get additional query and if that will stay intact.

I think we have filed the product from two of the facility, right? The other one is from CMO side.

We have done the dual filings for the product, right?

Abatacept was filed only from our Bachupally site.

Understood. That's helpful.

We'll get back in the queue.

Thank you, Tausif. The next question is from the line of Damayanti Kerai from HSBC.

Damayanti, please go ahead.

Hi. Thank you for the opportunity.

My question is again on semaglutide. As you continue to work towards resuming supplies after addressing the OOS issues, we understand in some of your targeted market new players are getting approvals, etc.

We understand you are B2B suppliers to a few of them, but nonetheless, by the time you get back in these market, how do you assess the competition scenario and your ability to gain market share there?

We believe right now that the demand for the 6 to 7 million pens will be there for us, and it's even backed with orders. We believe that we'll be able to sell all the 6 to 7.

Obviously, it's a bummer. We cannot deny it.

We see the consequence. We lost 4 months of sales for that, obviously from the 10, 11 to the 6, 7, this is the impact on us.

We feel that the demand for the product is still very high, and the people that will enter the market in these 4 months, to the best of our knowledge, they are not that many, at least in the markets that we are planning to get approvals. It's a bummer, but we believe that the product will stay solid for us.

Okay. Also wanted to understand this API issue, will it impact the review of application for semaglutide in some of the market, apart from obviously Canada is something where you have approved product, but say in Brazil or in other market, will the applications will be halted till the time you resolve the API issue?

No,

because the specs is stayed the same. We are not changing the specs or the quality.

It was just our ability to meet the specs in the scale-up batch on the API, which we need to resolve. The file is good, and the quality of the drug product is good.

I don't anticipate any delays or a change to our applications anywhere, including Brazil.

Okay. In how many countries you have filed semaglutide application so far?

How many we filed already?

More than 20-30 countries.

For sure. The program of the 80 countries remain the same.

If I remember correctly, but please forgive me if I'm not fully accurate, is around the 30 countries already, if I remember correctly.

Sure. My last question is how should we look at R&D and tax rate from here on?

We understand this quarter had some benefit on the taxes, but on a normalized basis, how should we look for the full year?

Our tax rate around between, I think, 24% to 25% on the full-year basis, and R&D what we have stated earlier, it is in the range of 7% to 8%.

Okay. Any major R&D programs after abatacept where you plan to spend majority?

We have a long pipeline for the future both on the peptides as well as additional biosimilars. This is likely that would be closer to the 7% like MVN said, but most of the R&D spend is right now going to products post-2034.

Between 2034 to 2040 type of that's where the R&D goes, beside of course some allocation that comes for licensing fee as well as remediation of product, but mostly it's for later product.

Sure. Thank you.

I'll get back in the queue.

Thank you, Damayanti. The next question is from the line of Saion Mukherjee from Nomura.

Saion, please go ahead.

Thanks for taking my question. Since we last addressed on the sema situation, is there any progress in terms of root cause analysis and how you see possibility of a resolution?

How do you sort of assess the risk of that program at this stage?

We identified the root cause. We started also the activities in the sites.

There is a program management that takes us again to around September 22nd, September 23rd. The success rate is high.

I don't know to say exactly percentage. If I need to throw a number, it's somewhere between 80% to 90%, but there is a chance that it will fail.

I just want to make sure. It's not 100%.

We feel relatively confident. Let's cross our fingers on that.

I see. Okay.

Just one last one on CapEx. What's the guidance for this year on CapEx and for next year, please?

We see, I think, this year close to at this point of time, I think around ₹1,800 crores on the full-year basis.

Will this come down next year, you think?

Hopefully, that's what is our expectations, but around that range, because at the end there's a continuously for the specific product investments in the biosimilars and the peptides and then regular CapEx as such. Okay.

Thank you, sir.

Already if you see that earlier we were in that ₹2,500 to ₹2,700 crores range, and then from there we have just this year's reducing to 1,800. I believe I think that stays at that level.

Okay. Sir, if I can just ask one question because you mentioned about Middle East conflict and freight cost, etc.

What's the level of impact either as a percentage of sale or in absolute amount, if you can quantify?

It would be both solvents and the freight on the EBITDA is close to around 1%.

Okay. Is there any improvement now because the conflict seem to have escalated once again?

How you see for the rest of the year?

We believe I think even as long as it continues, I know because earlier we thought suppose is stopped, then all the solvent prices and we have seen the decline. Now, because of once again the war is going on, we believe I think this will stay at least up to December this level of increase.

I see. Okay.

Thank you, sir.

Thanks, Saion. The next question is from the line of Rahul Jeewani from IIFL.

Rahul, please go ahead.

Thank you, sir, for taking my question. Sir, I wanted some clarity in terms of our base business growth.

Now, if I look at our North America revenue base in FY '22 was close to a billion dollars, and if I take this quarter's number, then we are annualizing at around $950 million. Now, over these past 4 years, we have launched around 90 to 100 products in US.

We did a main acquisition as well, which contributed $100 million in terms of incremental revenue. Despite these launches and main acquisition, where have we struggled in terms of driving growth on the base US business?

If you can please comment on that.

No, sure. Obviously, we faced on the base of the FY '22 or any other year that you are referring, a significant price erosions that was through this period of time.

In some of the years, it was even in double digit; in some of them, it was in single digit. This is, and you know that very well, very normal for the United States.

Against that, we brought new products. Some brought us more value and some less.

Overall, I'm reiterating what I'm saying all along, that the US market, the generic piece of it, is at best single-digit growth without the upside. From time to time, there is an upside that comes, and we had upside through the years, whether it was lenalidomide, and before that, there was other products.

That piece of the market is a single-digit, even low single-digit type of a market. In which new product compensate for price erosion.

That piece, the reason that we are still there, beside that is that this group of product is what's feeding the growth in emerging market as well as in Europe. The leverage growth and what you see now in Europe as well as in emerging market is primarily the US portfolio that is growing there.

We moved from investing in the US to take a product and launch it globally. Overall, the ROI of the product that we launched in the years that you mentioned are actually give us a very, very good ROI.

Just it's not coming in the United States, we see it in the other markets. In addition to that, we obviously diversifying ourselves to other business model as we stated.

To your analysis, you're correct in this period of time, if you take out product like lenalidomide, your analysis is correct.

Sure, sir. Do you think that we have lagged peers in terms of R&D productivity for the US generic business, given that many of our Indian peers have been able to launch products in, let's say, respiratory segment or injectables, which has allowed them to scale up their US portfolio, while we obviously seem to have had pretty muted performance on the US business over the past 4 to 5 year period?

Is there any issues in terms of the productivity for our R&D business, and do we have any measures in terms of evaluating this R&D productivity, particularly for the US generic business?

To your question, yes, we failed in certain complex generics. We've even stated some of them in the past like iron sucrose, like conjugated estrogen, like some of the peptides that we were late.

The answer is yes. We did have this issues.

I believe that we corrected it. Obviously, as we know very well, the R&D expenses of today's product that we will launch on average 10 to 12 years from now.

Obviously, the products that we launched in this period of time were products that were developed before that, and we absolutely had productivity issues, and I believe that we took the right measures to correct it. Again, I agree with your observation.

I believe that we took care of that.

Sure, sir. Last question from my end, on abatacept, I was also under the impression that we would file abatacept from the partner facility as well, but right now, you're saying that abatacept is only filed from Bachupally.

Do you see any risk to abatacept now in terms of, let's say, contributing to us in FY '28, and are we evaluating an alternate site filing for abatacept?

Abatacept was never meant to be filed from a CMO. It was developed and meant to be filed out of Bachupally from our CCM5, which is our drug substance, and our FFM2, which is the fill and finish, both of them in Bachupally.

That's was always the plan. There was some discussion in the past whether in a case of tariff, should we get a CMO in the United States?

We did engage with this issue, but a tariff way became not relevant, plus any CMO that will do now will have to be a post-approval supplement because first they will have to approve the product, and then based on that you can add information about the CMO. Any activity like that will be a post-approval supplement and will require also relatively high cost because, as CMO of biologics product is not cheap.

At the moment, the launch will be out of Bachupally. About the risk, there are two types of risk.

One is in a case that we will have additional query on the GMP, and I believe that is addressable like I mentioned, but it is possible to get. Second query is about the queries that we may get on the BLA.

If we will get, that's naturally can delay the launch of abatacept. As we speak today, the goal date for abatacept is in mid-December 2026.

Sure, sir. That's it from my side.

Thank you.

Thanks, Rahul. The next question is from the line of Vivek Agrawal from Citi.

Vivek, please go ahead.

Thanks, Aishwarya. Thanks for the opportunity.

Just want to understand with the India business, they have done good growth in the quarter. Just want to understand what the organic growth if we remove couple of small acquisitions that we have made in this quarter.

Thank you. India.

In India, if we remove the recent acquisition, it's 15%?

15.5%.

15.5% fully organic.

Understood. Does that include semaglutide supply as well?

Not much, Vivek.

Understood. Thank you.

Just one more question on bosutinib. Does that include a full-quarter impact of launch, or it's just a very small launch in this quarter?

It's 1 month.

Less than a month, actually.

Less than a month.

It's 2 weeks of supply, and we have exclusivity on the 400 mg.

Understood. Thanks.

That's from my side. Thank you.

Thanks, Vivek. The next question is from the line of Dr.

Bino Pathiparampil from Elara Capital. Bino, please go ahead.

Hi, good evening. Just couple of quick questions.

One, in Canada, I believe we had an arrangement to provide semaglutide to Sandoz as well. Does that deal still hold, and are they going to wait for our supplies to be back?

It's still hold, and we believe that if supply will come back in November, we'll be able to meet the commitment to Sandoz.

Got it. Second, on bosutinib, I believe it's a partner product.

You are selling it in the market. What would be the broad profit-share arrangement?

Is it equal, or do you make only a distribution margin?

Overall, if you see, this margin from this product is above company-average margin.

Got it. Thank you.

Thanks, Bino. The next question is from the line of Surya Patra from PhillipCapital.

Surya, please go ahead.

Thanks for the opportunity. My first question is about the NRT.

You mentioned in your opening remarks that we have seen a decline this quarter. This is after complete integration of the acquisition.

Can you give some sense that, okay, what led to this kind of decline and whether this is a kind of a trend likely to be seen even subsequent quarters?

No, the trend is a trend of growth. What we had this quarter is that in some markets, because of the cut-off and inventory that were in a market, we did not sell in some weeks in this quarter, and that's what led to that, plus the timing of the tender in Brazil, in which we won, but we sold more in the quarter, and we did not sell in this quarter.

Overall, you should see continued growth and very, very healthy margins. Far, good on this one.

Apart from what Erez said, Surya, another one is because till March 2026 last year, I think we were just depending on Haleon. I think they were doing, then we are paying certain fee.

This year, we completed the integration by March 2026. Then entire sales we are operating, and then as part of this new model, and then what the Haleon was offering earlier, rebates and discounts were not impacting the sales line, but this year, now, since we have directly distributing the product to the distribute customers, and then what the rebate discounts, I think we are giving, that is now part of the gross-to-net in the revenue line.

Then corresponding, there is a SG&A reduction. Overall, if you look at on the profit, it is a neutral.

Absolutely, there is no impact. Then it is a continuously overall of this business EBITDA's margin is very healthy, and the business momentum is continuing in the very right direction.

Yeah.

All right, thanks, Surya. The next question is from the line of Shashank Krishnakumar from MK Capital.

Shashank, please go ahead.

Hi. Thanks for taking my question.

Erez, my first one was on our rituximab filing. I think one of our competitors has received interchangeability recently.

Does our filing also include comparative data so that on approval would we also get interchangeability on this product?

Rituximab.

Our rituximab for sure would be interchangeable. As we got delays because rituximab approval in the United States got delayed.

For us, it's mostly to obtain approvals because the US FDA inspection, PLI, was for both abatacept and rituximab. Once we go, our partners will not have a problem to switch products.

Our products will be also interchangeable.

Got it. Thank you.

That's helpful. Second one on denosumab, I think obviously, our filing was stuck because of issues at our partner's facility.

I believe our partner has addressed the FDA's observations, but the resubmission obviously has to happen at our end. Have we resubmitted the BLA for denosumab?

The BLA is coming only from our partner. He is also making the products in that, and we are now in discussions with the partner of what to do with this product.

Got it. Thank you.

That's it from my side.

Thanks, Shashank. Participants are requested to restrict the number of questions to just one to ensure that everyone on the call gets an opportunity to interact with management.

The next question is from the line of Yogesh Soni, Haitong Securities. Yogesh, please go ahead.

Hello,

thanks for the opportunity. My question is with regards to the semaglutide API provision that you have taken.

If you could help us understand had this provision not been taken, what would have been the pen volume that would have been sold? The question is coming to understand what is the opportunity lost that we have faced as a result of this API provision.

The opportunity is about 3 to 4 million pens, assuming that we are coming back in November.

Understood. Thank you for that.

Second question is just to understand, in 1 and 1/2 months of commercialization in this Canada market, what kind of market share did we enjoy in the semaglutide space?

We did not have the chance to sell much, I cannot really speak on market share. Obviously, we were one of the first to launch along with Apotex, naturally, by the time that we'll come back, we'll probably not be going to be only the two of us.

Naturally, when you are two, it's a relatively high market share, but we did not manage to get market share per se as we did not sell much.

If I can squeeze in one more question. Given that we are looking to resume the supplies from November, what gives us the confidence of doing around 6 to 7 million pens given that Apotex would have already scaled up its market share in the next 3 to 4 months?

How difficult does this target seems to us?

The confidence is high. It's not just Canada for us.

By that period of time, we'll have approval in quite a few markets, plus we have engagement with partners. We mentioned some of the names.

The confidence is very high. Actually, all of our partners are looking forward that we'll come back.

Like I mentioned before, I believe that we will have a solid demand for this 6 to 7 million pens, and also I believe that our relationship with our partners will allow to make us this product as required. We just need to give them the API.

Thank you, Erez, for your clarifications.

Thanks, Yogesh. I would once again request everyone to restrict the number of questions to just one since we have many in the question queue.

The next question is from the line of Amlan Jyoti Das from J.P. Morgan.

Amlan, please go ahead.

Can you hear me? Sorry.

Yes.

My question is regarding the Canada market. We have seen that a third competitor has also gotten approval recently, and one of the other competitors are targeting a December end approval.

With three to four players in the market, what kind of pricing do you see in the Canada market when supply resumes for you in November?

The partner that got approval is using our products. I'm not anticipating any more prices because the price went day one to the type of market that reflect the three players and above.

I do not anticipate additional kind of reimbursement pricing. Naturally, once we'll come back and we'll see how many more, we may have to change rebates or stuff like that.

This is yet to be seen. At the moment, also the one that got approval is waiting for us to resolve the operational issues.

Just to put it a perspective, what kind of prices we expect then? Would it be in the range of $30, say, or will be lower than that?

Could you just quickly give us a directional sense on that?

As when I discuss it in previous meeting, the price in Canada is 78 Canadian, and then from that, you need to have the margins that you need to give to the relevant retailers, depends on the type of market that you do, whether it is a private market, public market, or cash market. It is range from 38%, which is for the retail and for what you call the private market, and then in according, depends of how many patients are also reimbursed by the relevant provinces, you may need to give additional 5% to 6% to the relevant province.

That did not change from our previous meetings. It's the same set of numbers.

Okay. Thank you.

My next question is about the US. Yeah.

You have guided for double-digit growth in the US. Is it the guidance for the base business excluding semaglutide, or just wanted a clarification on that?

Semaglutide is in Canada, we are not selling in the United States. It's without semaglutide and without lenalidomide.

Sorry?

Okay. Excellent.

Understood. Primarily for the US, it will be double-digit growth.

It's a double-digit growth and was already that this quarter, yeah.

Perfect. Thanks.

Thanks, Amlan. The next question is from the line of Sumit Gupta from Antique Stock Broking.

Sumit, please go ahead.

Hey, hi. Thanks for the opportunity.

Sir, what are the biologics sales globally as of now, and when can we expect it to break even?

Sorry, again?

Biologics.

On the biologics sales, how much is it now?

It's about 2% of the overall. Around.

It's about 2% of our sales, and we are supposed to be profitable at the day that we launch abatacept.

Okay. How should we see abatacept going forward, let's say, over the next 2 to 3 years?

What will the timeline do you expect?

We submitted the IV products in the United States. Like I mentioned before, December is the goal date.

That's the earliest we can get approval. We can launch upon approval.

The Europe IV was also filed, but is very, very small because in Europe, it's primarily the sub-Q. In terms of the sub-Q, it will be in 2028, likely around March of '28 or February or March '28, United States, and probably around September to October in Europe.

Understood, sir. Thank you.

Thanks, Sumit. The next question is from the line of Vishal Manchanda from Systematix.

Vishal, I would request you to restrict yourself to just one question, please.

Hi. Thanks for the opportunity.

On our biologic plant inspection, can you share whether we had any observations related to sterility assurance?

No, there is not as such, and like I mentioned before, all the observations are addressable, and we already answered them.

Do you expect any scale-up issues in abatacept like we saw in semaglutide?

It's obviously very, very different product. I hope not.

We are not planning that. In pharma, you never know.

Right now, we are optimistic.

Got it. PLI incentives, if you can call out, do we expect any meaningful number here?

In the first-quarter financials, no PLI.

Yeah. Anything in the next 9 months meaningful?

Once, I think, semaglutide supply resumes, I think as for PLI scheme also we should have for the set of products minimum growth. Once we assess and then if the growth is there, and then PLI we start accounting.

Got it. Thank you.

All right. In the interest of time, we will

just Continue. Continue.

We can allow them. Okay.

The next question is from the line of Krishnendu Saha from Quantum Mutual Funds. Krishnendu, please go ahead.

Can you hear me? Hello?

Yes.

Yes.

Yeah. Just quickly, we're supplying to partners like Sandoz, Aspen, and others.

Is there any penalty we have to pay for failure to supply?

Failure to supply?

Here as per what the orders were received from Indian like a Torrent and USV. Whatever is as per the agreement, suppose whatever it is, that's already taken care.

Then in case of Sandoz, Aspen, I think at this point of time, we don't expect any such claims.

Okay. Just to jog my memory, the API is being supplied from a US FDA plant, or which plant is it coming from?

This is from our Vizag plant, CTO

6.

It's a US FDA-approved plant.

If there's a OAI from this plant, does our approval in Canada does it set us back?

Sorry.

Sorry. Sorry.

There is no OAI.

There is no OAI.

Thinking out loud.

If there will be an OAI, then it will affect the US, maybe the Canadian will that, but it's a very hypothetical because the US inspected the plant already this year, and we got approval. Not relevant.

As a hypothetical question, Canadian and American are different regimes.

It's from the Indian plant. Okay.

This 40 mg which we have exclusivity, how big is the market size, just for my knowledge, please?

400 mg, you mean? Sorry.

400.

Yeah. Sorry, my mistake.

I think overall the product is a large one. It's in billions.

Just the 400 mg, any idea?

We will come back on that, sorry.

I think Aishwarya will just come back.

How is the nicotine patch doing for us as of now? Any growth rate you're seeing out there?

Because it's a profitable business for us. Can you just give me your thoughts on that, please?

It's a profitable, and it is growing, and we are very happy with it. We answered these questions before.

Guys, if we can not repeat questions, we're happy to give our time, but please let us

Sure. Thank you.

Thank you very much.

Just to answer your question, bosutinib is about $300 million as far as the market is concerned.

Market size,

yeah. Thank you.

The next question is from the line of Rupesh Tatia from Launch Equity Capital. Rupesh, please go ahead.

Hi. Am I audible?

Yes.

My question is on interchangeability in Canadian markets. There are these various provinces which gives out interchangeability designation, and also I think private insurers also give interchangeability designation.

Most of this insurance has a clause of mandatory generic substitution. Could you give color that what does it take to get this interchangeability designation and when that happens, my expectation is all of the prescription volume will move to generic.

When do we expect that to happen? Any color on that will be helpful.

The other aspect also is the innovator's product is recombinant product, and our product is synthetic product. Does that create some problems for this interchangeability tag?

There is no problem with interchangeability in any market. The product is approved as generics, and the type of the API doesn't affect it.

The semaglutide is approved as a generic product. No issues of interchangeability, and you don't need to prove anything beyond what the normal submissions.

We had to show obviously comparability as well as all the relevant safety like immunogenicity and other data.

Next year then, generic will have 80%, 90% market share in Canada. Is that a fair thing to assume?

I don't know about that. It's about also the confidence of the people.

At least at the launch time, the allocation of the retailers assume 60%, and then will grow.

Insurance-driven market, pardon for interruption, insurance-driven market. I'm not asking about out-of-pocket or retail.

I'm trying to answer that. It started with 60% and likely to go higher.

What exactly the number will be, I don't know, but yeah, I believe that as the confidence and the supply will be there, it's going to be primarily generic market, yeah.

Okay. Then just quickly, when do we expect Brazil approval for us or our partner, any time estimate you can give?

It should be shortly. All this stuff about the rejection, that was reversed, and we are expecting approval in next few weeks.

Okay.

Thank you. Thank you for answering my questions.

In the interest of time, we'll take one last question from Saion Mukherjee. I think he's joined back the queue.

Saion?

Thanks for taking the follow-up. A couple of questions.

In the US, I think you mentioned 20, 25 launches. How many we are expecting through the rest of the year, and are there any material launches that are lined up or you expect?

Altogether, right now, we are targeting 27. At least we are supposed to have reasonable launch.

Let's call it, I cannot share yet the name of the product, already in the next a couple of weeks. In the second quarter.

How large is the opportunity? Can you give an idea about the size or the revenue potential from that launch?

It should be in the range of tens of millions of dollars, that specific launch.

Okay. Thank you.

MVN, if you can talk about, I understand biologics and peptide facility operations are not generating any revenues at this point. What's the revenue-cost mismatch there?

What's the cost that is hitting the P&L on account of this, which is not generating any revenues?

In the biologics already we invested for CCM5 for abatacept, certainly we are just waiting for approval. Then whatever is expenses is already it is heating in our P&L.

Similarly, what the capacities we have created for peptides both for API and formulations, fill-finish also, it is there. Once these two products comes back, and definitely then it will give the profit positive.

I was wondering if you can quantify the amount of cost that you're incurring on account of these two at this point.

Maybe I'll just come back.

Okay. Okay.

Thanks.

Thank you, yeah.

That was the last question. Thanks, Saion.

Thank you, everyone, for joining us today. We value your time and your participation on this call.

If you have any further questions or need any additional information, please do feel free to reach out to me. With that, we conclude today's earnings call.

Thank you. Thank you very much.

Thank you.